Paola Di Gennaro

Dr. Paola Di Gennaro


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Cancer Letters
Verified
Journal Article
Closed access
GCGiuseppina Comito
Giuseppina Comito
Elisa GiannoniElisa Giannoni
Elisa Giannoni
PGPaola Di Gennaro
Paola Di Gennaro
CSCoral Pons Segura
Coral Pons Segura
GGGianni Gerlini
Gianni Gerlini
PCPaola Chiarugi
Paola Chiarugi

30 July 2016 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
PGPaola Di Gennaro
Paola Di Gennaro
GGG. Gerlini
G. Gerlini
CUCarmelo Urso
Carmelo Urso
SSS. Sestini
S. Sestini
PBP. Brandani
P. Brandani
LBL. Borgognoni
L. Borgognoni

1 March 2018 in Cancer Letters
Verified
Journal Article
Closed access
PGPaola Di Gennaro
Paola Di Gennaro
GGG. Gerlini
G. Gerlini
RCR. Caporale
R. Caporale
SSS. Sestini
S. Sestini
PBP. Brandani
P. Brandani
LBL. Borgognoni
L. Borgognoni

Verified
Journal Article
Open access
PDF file
GGGianni Gerlini
Gianni Gerlini
PGPaola Di Gennaro
Paola Di Gennaro
NPNicola Pimpinelli
Nicola Pimpinelli
SSSerena Sestini
Serena Sestini
LBLorenzo Borgognoni
Lorenzo Borgognoni
Langerhans cells (LCs) are crucial regulators of anti-cancer immune responses. Cancer, however, can alter DCs functions leading to tolerance. The enzyme indoleamine 2,3-dioxygenase (IDO1) plays a crucial role in this process. In sentinel lymph nodes (SLNs) of patients with melanoma, LCs show phenotypical and functional alterations favoring tolerance. Herein we aimed to investigate IDO1 expression in SLN LCs from patients with melanoma. We showed by immunofluorescence analysis that a portion of Langerin+ LCs, located in the SLN T cell-rich area, displayed the typical dendritic morphology and expressed IDO1. There was no significant difference in the expression of IDO between SLN with or without metastases. Double IDO1/CD83 staining identified four LCs subsets: real mature IDO1−CD83+ LCs; real immature IDO1−CD83− LCs; tolerogenic mature IDO1+CD83+ LCs; tolerogenic immature IDO1+CD83− LCs. The latter subset was significantly increased in metastatic SLNs as compared to negative ones (p < 0.05), and in SLN LCs of patients with mitotic rate (MR) > 1 in primary melanoma, as compared to MR ≤ 1 (p < 0.05). Finally, immature SLN LCs, after in vitro stimulation by inflammatory cytokines, acquired a maturation profile by CD83 up-regulation. These results provide new input for immunotherapeutic approaches targeting in vivo LC of patients with melanoma.

1 February 2014 in Journal of Dermatological Science
Verified
Journal Article
Closed access
PGPaola Di Gennaro
Paola Di Gennaro
MRMaria Raffaella Romoli
Maria Raffaella Romoli
GGGianni Gerlini
Gianni Gerlini
MDMassimo D’amico
Massimo D’amico
PBPaola Brandani
Paola Brandani
LBLorenzo Borgognoni
Lorenzo Borgognoni

30 August 2017 in Cellular Immunology
Verified
Journal Article
Closed access
MRMaria Raffaella Romoli
Maria Raffaella Romoli
PGPaola Di Gennaro
Paola Di Gennaro
GGGianni Gerlini
Gianni Gerlini
SSSerena Sestini
Serena Sestini
PBPaola Brandani
Paola Brandani
LBLorenzo Borgognoni
Lorenzo Borgognoni